- Record: found
- Abstract: not found
- Article: not found
Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma
Keith M. Sullivan ,
Ellen A. Goldmuntz ,
Lynette Keyes-Elstein ,
Peter A. McSweeney ,
Ashley Pinckney ,
Beverly Welch ,
Maureen D. Mayes ,
Richard A. Nash ,
Leslie J. Crofford ,
Barry Eggleston ,
Sharon Castina ,
Linda M. Griffith ,
Julia S. Goldstein ,
Dennis Wallace ,
Oana Craciunescu ,
Dinesh Khanna ,
Rodney J. Folz ,
Jonathan Goldin ,
E. William St. Clair ,
James R. Seibold ,
Kristine Phillips ,
Shin Mineishi ,
Robert W. Simms ,
Karen Ballen ,
Mark H. Wener ,
George E. Georges ,
Shelly Heimfeld ,
Chitra Hosing ,
Stephen Forman ,
Suzanne Kafaja ,
Richard M. Silver ,
Leroy Griffing ,
Jan Storek ,
Sharon LeClercq ,
Richard Brasington ,
Mary E. Csuka ,
Christopher Bredeson ,
Carolyn Keever-Taylor ,
Robyn T. Domsic ,
M. Bashar Kahaleh ,
Thomas Medsger ,
Daniel E. Furst
January 04 2018
January 04 2018
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d5058878e393">Despite current therapies, diffuse cutaneous systemic
sclerosis (scleroderma) often
has a devastating outcome. We compared myeloablative CD34+ selected autologous hematopoietic
stem-cell transplantation with immunosuppression by means of 12 monthly infusions
of cyclophosphamide in patients with scleroderma.
</p>